英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
dohickey查看　dohickey　在百度字典中的解释百度英翻中〔查看〕
dohickey查看　dohickey　在Google字典中的解释Google英翻中〔查看〕
dohickey查看　dohickey　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home | BridgeBio
    BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers
  • BridgeBio Pipeline – Explore Targeted Genetic Therapies
    Explore BridgeBio’s drug development pipeline, including clinical and preclinical programs advancing precision medicines for genetic diseases
  • Careers - BridgeBio
    BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers
  • BridgeBio Pharma Inc. - Investor Relations
    BridgeBio exists to develop transformative medicines for genetic conditions Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations Our
  • About | BridgeBio
    BridgeBio is a biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers
  • BridgeBio Pharma Inc. - BridgeBio to Participate in the J. P. Morgan . . .
    PALO ALTO, Calif , Jan 05, 2026 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph D , will present at the 44 th Annual J P Morgan Healthcare Conference in San Francisco, CA on Monday, January 12 at 7:30 am PT To access
  • BridgeBio Pharma Inc. - News
    BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 Download , BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1, May 12, 2026, (opens in new window) May 11, 2026 Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart
  • BridgeBio Pharma Inc. - BridgeBio Reports Fourth Quarter and Full Year . . .
    $154 2 million in total fourth quarter revenues, net, and $502 1 million in full year revenues, net, primarily comprised of net product revenue of $146 0 million and $362 4 million, respectively BridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed
  • BridgeBio Pharma Inc. - Events Presentations
    Aim for 1-2 sentences that describe the subject, setting, or actions
  • BridgeBio Pharma Inc. - BridgeBio Submits NDA to FDA for Encaleret for . . .
    About BridgeBio BridgeBio exists to develop transformative medicines for genetic conditions Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging





中文字典-英文字典  2005-2009